---
slug: the-disc-stack
title: The Disc Recovery Stack
canonical: https://miscsubjects.com/a/the-disc-stack
---

A disc stack is two or more compounds taken at the same time for a worn or bulging spinal disc — most often BPC-157 with TB-500, sometimes with ARA-290 added for the leg pain, sometimes alongside a weight-loss drug. Each compound is aimed at a different step in how a disc fails.

Underneath all of it is one arithmetic. A disc is being broken down at some speed and built back at some other speed, and how your back feels in six months is decided by which of the two is faster. Every single thing on the list below — walking, smoking, a needle, a tablet, a vial — moves one of those two speeds by some amount. What decides your outcome is not any one of those amounts. It is the sum.

That sum is what almost nothing has been measured on. Nobody with a bad disc runs one variable. They are walking or not walking, sleeping six hours or eight, carrying an extra thirty pounds or not, taking ibuprofen daily or not, and injecting one compound or three — all in the same week. The individual numbers below are real and mostly good. The combined numbers, with three exceptions, do not exist, and where they do exist one of them came back negative.

## A worn disc is two speeds, and the slow one is the blood supply

The disc is the largest structure in the body with almost no blood supply of its own. Small vessels reach the outermost fibres of the tough outer ring and stop there; the soft centre is fed by fluid seeping through the bone above and below it. Every repair process in the body runs on blood delivery, so the disc rebuilds more slowly than any other load-bearing tissue you own.

[[embed:source:s1]]

That does not mean the rebuild side loses. Pooled across eleven cohort studies of people managed without surgery, 66.66% of herniated discs shrank on their own (95% CI 51% to 69%). In the United Kingdom subset the figure was 82.94%; in the Japanese subset, 62.58%.

[[embed:source:s2]]

The shrinking is done by immune cells that treat the displaced fragment as foreign material, digest it, and bring new blood vessels in behind them to carry the debris away.

[[embed:source:s3]]

Two things follow from that pair of facts, and they set up everything else. First, the rebuild side already wins about two times in three with nobody doing anything. Second, the mechanism it wins by is inflammation plus new blood vessel growth — which is precisely the mechanism a daily anti-inflammatory tablet is designed to shut down.

[[embed:degenerative-disc-disease]]

## Genetics puts a number on each thing that wears a disc down

Observational studies of back pain are badly confounded: people who smoke also move less, weigh more and sleep worse, so an association tells you almost nothing about direction. Mendelian randomisation gets around that by using inherited gene variants as the exposure — you are assigned your variants at conception, before any lifestyle exists, so the arrow can only point one way.

A 2026 synthesis pooled twenty such studies in people against disc degeneration and put an odds ratio on each factor. An odds ratio of 1.26 means roughly a 26% higher chance of the outcome per unit of the exposure.

| What moves the breakdown speed | Odds of disc degeneration | How to move it |
|---|---|---|
| Time spent sitting watching television | 1.78 (1.52–2.08) | Stand up and walk; this is the largest lifestyle number in the set |
| Body mass index | 1.26 (1.14–1.38) | Weight loss by any route |
| Waist circumference | 1.26 (1.04–1.53) | Same lever, measured at the belly |
| Smoking, ever having started | 1.22 (1.12–1.33) | Stopping — with a caveat below |
| Triglycerides in the blood | 1.08 (1.03–1.13) | Diet, weight loss, movement |
| Type 2 diabetes | 1.05 (1.03–1.07) | Glucose control |
| Higher bone density | 1.20 (1.15–1.25) | Not a lever — you would not lower it on purpose |

[[embed:source:s8]]

The body-mass row has a second, condition-specific measurement behind it. A meta-analysis of observational studies in people found overweight raised the odds of nerve-root leg pain by 1.23 and obesity by 1.40 — the same direction as the genetic estimate, in the exact symptom most people with a disc actually have.

[[embed:source:s4]]

Read the television row again, because it is the one nobody talks about. Genetically predicted television time carried a larger effect on disc degeneration than smoking, weight, blood fats and diabetes. Sitting still is the biggest modifiable factor in the whole causal set.

On stopping smoking, the honest answer has a limit in it. Rats exposed to cigarette smoke for eight weeks developed cracked, torn, misaligned outer rings and fibrous tissue in the soft centre. After they stopped, the degeneration stopped getting worse and the soft centre regained some of its gel-like material. The physical misalignment of the outer ring did not come back, and the inflammatory signal IL-1beta was still raised eight weeks after the last cigarette.

[[embed:source:s17]]

So stopping smoking halts the slide and buys back part of the chemistry, and does not undo the structural damage already done. That distinction — halting versus reversing — applies to almost every item on this page.

Two more entries on the breakdown side, both self-inflicted by treatment rather than by lifestyle.

Repeated steroid injections into the spine cost bone. Three thousand injected patients were compared with three thousand matched controls; each successive injection raised the risk of a vertebral fracture by a factor of 1.21 (95% CI 1.08 to 1.30). One injection is a small bill. A course of six is a compounding one.

[[embed:source:s14]]

Months of daily anti-inflammatories buy less pain relief than most people assume and work against the clearance mechanism described above. Pooled across 32 trials and 5,356 people with acute back pain, the drugs beat placebo by 7.29 points on a 0–100 pain scale — a difference the Cochrane reviewers called small and probably not clinically relevant.

[[embed:source:s21]]

[[embed:bpc-157-vs-nsaids]]

## Walking is the only item on this page with a hazard ratio behind it

WalkBack randomised 701 Australian adults who had just recovered from a back pain episode into either an individualised, progressive walking programme with six physiotherapist sessions over six months, or no treatment at all. The walking group went a median 208 days before their next activity-limiting episode (95% CI 149–295). The control group went 112 days (89–140). The hazard ratio was 0.72 (95% CI 0.60–0.85, p=0.0002) — meaning that at any given moment, a walker's chance of the pain returning was 28% lower.

[[embed:source:s7]]

Two details in that trial matter for anyone assembling a combination. It cost AU$7,802 per quality-adjusted life-year, which made it cost-effective with 94% probability. And it was not free of harm: lower-limb adverse events ran 100 in the walking group against 54 in the control group.

For pain that is already chronic rather than recurring, structured exercise pooled across 249 randomised trials in people produced roughly a 15-point improvement on a 0–100 scale against no treatment or usual care — about double what an anti-inflammatory delivers for acute pain, and roughly five times what one delivers for chronic pain.

[[embed:source:s10]]

That is the whole evidence-based core of a disc recovery plan, and it is walking and loading. Everything else on this page is added on top of it, and nothing else on this page has a number that comes close.

## Three things sold as the raw material for the rebuild were tested and did nothing

The intuition that a rebuilding tissue needs feeding is reasonable. The intuition has been tested three times and lost three times, and a page that skipped that would be selling something.

Collagen. Thirty-nine recreationally active men took either 15 g of collagen peptides daily or a placebo through 15 weeks of supervised lower-body resistance training. Both groups gained tendon stiffness (+17.3% collagen, +20.9% placebo) and Young's modulus (+17.8% versus +20.6%). Between the groups, nothing: no difference on any tendon measure, with p-values between 0.365 and 0.877. The training built the tendon. The powder added nothing detectable.

[[embed:source:s12]]

Vitamin D. Ten randomised trials in people with chronic low back pain, pooled: standardised mean difference −0.130 (95% CI −0.260 to 0.000), which touches zero. Long-term dosing did not help either, and neither did the active forms. Baseline vitamin D status made no difference to the result.

[[embed:source:s13]]

Weight loss on its own, once exercise is already in place. Across 22 trials and 3,602 people, weight-loss interventions beat minimal care on pain (SMD −0.54) — but head to head against exercise alone, in four trials and 673 people, weight loss was no better (SMD −0.13, 95% CI −0.40 to 0.14). The credibility of the whole body of evidence was rated very low.

[[embed:source:s11]]

That last result is a compounding finding, not a single-factor one, and it is the first of only three real interaction measurements on this entire page. Weight loss and exercise are not additive in the way the arithmetic of the two-speeds model would suggest. They overlap. Buying both does not buy you twice.

## Each peptide is aimed at a different step, and none has been put near a disc

BPC-157 is a fifteen-amino-acid chain based on a sequence found in human stomach fluid. In rats it raises VEGF, the signal that grows new blood vessels into damaged tissue, and drives connective-tissue cells to move into an injury and rebuild it. A cut rat Achilles tendon treated with it came back mechanically stronger than an untreated one.

[[embed:bpc-157]]

TB-500 is a seven-amino-acid fragment of a larger natural protein, thymosin beta-4. In animals it acts on cell movement and on the organisation of collagen laid down in a healing wound. The molecule in the vial and the molecule in most of the published research are not the same thing, which is covered in full on its own page.

[[embed:tb-500]]

The reason a nerve compound is in a disc stack at all is that a large share of the pain is chemical rather than mechanical. Material leaking from a torn disc releases TNF-alpha and IL-1beta onto the nerve root, and those two signals are the ones tied to both the ongoing breakdown of the disc and the pain itself.

[[embed:source:s5]]

ARA-290 is the only one of the three with randomised human evidence of any kind. In a 28-day phase 2b trial, 64 people with sarcoidosis-related small nerve fibre loss and nerve pain took 1, 4 or 8 mg a day or placebo. At 4 mg the corneal nerve fibre area rose by 697 µm² over placebo (95% CI 159–1,236, p=0.012), and regenerating skin nerve fibres rose too (p=0.035). Pain improved in every group including placebo; the placebo-corrected pain difference in the moderate-to-severe subgroup did not reach significance (p=0.157).

[[embed:source:s16]]

[[embed:ara-290]]

Read that carefully, because it is the strongest human result any compound in this stack has, and it is about a nerve in an eye of a person with sarcoidosis. Nobody has run ARA-290 against a nerve root squeezed by a disc. Human evidence in one tissue and one disease does not transfer to another by argument.

Retatrutide is not a disc compound at all. It is a weight-loss drug, and its only relevance here runs through the body-mass row of the table above: less load on the column, no direct action on disc tissue.

[[embed:retatrutide]]

[[embed:what-are-peptides-herniated-disc]]

## The one experiment that tested the pair found no bonus for taking both

This is the single most important result on this page, and it is the one that the phrase "the repair pair" was invented before anybody had.

In 2026, 32 male Sprague-Dawley rats, each about 330 g, had their Achilles tendon cut and repaired, then were split into four groups of eight: control, BPC-157 at 10 µg/kg/day, TB-500 at 60 µg/kg/day, and both together. Everything was injected into the belly, daily, for four weeks.

Results, arm by arm:

| Arm | Load to failure | Tissue architecture score | Verdict |
|---|---|---|---|
| Control | baseline | baseline | — |
| BPC-157 alone | higher, not statistically significant | numerically better, not significant | signal without proof |
| TB-500 alone | higher, significant (p<0.05) | Bonar p=0.016, Movin p=0.017 | the only arm that moved the mechanical number |
| Both together | not significantly better than either alone | Movin p=0.040 | no bonus for the second compound |

The authors' own sentence: "Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone."

[[embed:source:s9]]

Their proposed explanation is that the two compounds converge on the same downstream machinery, so the second one has nothing left to add. They flag it as a hypothesis needing confirmation.

Now negate it properly, because a single result does not settle a question in either direction. Eight rats per arm is small. An additive effect of, say, 15% would very likely be missed at that sample size. The endpoint was a tendon at four weeks, not a disc at six months. The route was into the belly, which is not how anybody takes either compound. And no dose-response work was done, so a different ratio of the two might behave differently. What the experiment establishes is narrow and real: at these doses, in this tissue, on these endpoints, the pair did not beat the better single compound. What it does not establish is that combining them is pointless everywhere.

The claim it does damage to is specific. Anyone who tells you the two compounds are synergistic is describing a mechanism, not a measurement. The measurement exists, it was taken in 2026, and it came back flat.

## Six real combinations, side by side

Nobody chooses one row of the tables above. They choose a whole column of behaviour. Here are six combinations a person with a bad disc actually ends up in, with what is known about each part, what is known about the parts in combination, and where the interaction has never been measured.

| The combination | What each part is measured at, alone | What is measured about the combination | Never measured |
|---|---|---|---|
| **A. Walking 25 min/day + adequate protein + BPC-157 + TB-500** | Walking: hazard ratio 0.72, 701 people, HUMAN. Protein/collagen: no tendon effect over placebo in 39 men, HUMAN. BPC-157: rat tendon repair, ANIMAL. TB-500: rat tendon repair, ANIMAL | The two peptides together: no benefit beyond either alone in 32 rats, ANIMAL | Walking with either peptide, in any species. Any of it in a human disc |
| **B. Smoking + no movement + repeated steroid injections + daily anti-inflammatories** | Smoking: odds 1.22, HUMAN. Sitting: odds 1.78, HUMAN. Each steroid injection: 1.21× fracture risk, HUMAN. Anti-inflammatories: 7.29/100 points of pain relief and suppression of the clearance mechanism, HUMAN | Nothing. Not one study has combined these four | Everything. This is the most common real-world combination and the least studied |
| **C. Walking alone, nothing else changed** | Hazard ratio 0.72 for recurrence; ~15/100 points for chronic pain across 249 trials, HUMAN | This is the measured baseline every other row should be compared against | — |
| **D. Both peptides, no change to movement or weight** | Rat tendon data only, ANIMAL | The pair, in rats: no additive benefit, ANIMAL | Whether peptides do anything at all when the load driving the damage is unchanged |
| **E. Weight loss on a GLP-1 drug + walking, no peptides** | Weight: odds 1.26 per unit of body mass index, HUMAN. Walking: hazard ratio 0.72, HUMAN | Weight loss versus exercise alone, head to head: no added benefit, 4 trials, 673 people, HUMAN | Retatrutide specifically — a 586-person trial is running and reports in 2027 |
| **F. Everything: walking + weight loss + BPC-157 + TB-500 + ARA-290** | Each part as above; ARA-290 has 64-person HUMAN data in a different disease | Nothing whatsoever | The entire combination. No study in any species has given three of these compounds together |

Read column three. Across six combinations, the total measured interaction evidence is three findings: weight loss adds nothing on top of exercise in people, the two peptides add nothing on top of each other in rats, and nothing else has been looked at.

## The interactions nobody has measured, written down so the holes are visible

Naming a gap is a finding. These are the specific pairs and triples that a person assembling a stack is implicitly betting on, with no measurement behind them:

- BPC-157 combined with any form of exercise, in any species.
- Either peptide combined with an anti-inflammatory drug — which matters, because the drug suppresses the same new-blood-vessel step the peptide is proposed to drive. Rats given BPC-157 alongside diclofenac had less gut damage, but nobody measured the tendon.
- ARA-290 combined with either of the other two, in any species.
- Any of the three during active shrinking of a herniation, where the body's own immune clean-up is already running.
- Weight loss combined with either peptide.
- All three peptides together, which is what the popular stack actually is.
- Any of it against the 66.66% background rate of the disc fixing itself. This is the sharpest hole: without a control arm, a person who improves on a stack cannot tell whether the stack did it or whether they were in the two-thirds.

## Every claim above, against the thing that would break it

A claim counts as established only after it has survived its own negation. Here is each substantive claim on this page put against what would falsify it, and whether that test has been run.

| Claim | Tier | What would break it | Has that been tested? |
|---|---|---|---|
| Most herniations shrink without treatment | HUMAN | A cohort where imaging shows no change in most people | Tested repeatedly; 11 cohorts pooled at 66.66% |
| Walking lowers the recurrence rate | HUMAN | A randomised trial where the walking arm relapses as fast as controls | Tested; 701 people; walking arm went 96 days longer |
| Sitting is the largest modifiable driver of degeneration | HUMAN | A causal-genetic study putting television time below smoking or weight | Tested in 20 pooled studies; television time came out highest at 1.78 |
| Supplying raw material speeds tissue rebuilding | HUMAN | A trial where collagen plus training beats training alone | Tested; 39 men, 15 weeks, no between-group difference |
| Vitamin D helps chronic back pain | HUMAN | A pooled result whose confidence interval excludes zero | Tested; 10 trials; interval touches zero |
| Weight loss adds to exercise | HUMAN | A head-to-head trial where the combined arm beats exercise alone | Tested; 4 trials, 673 people; no added benefit |
| BPC-157 and TB-500 are synergistic | ANIMAL | An experiment where the combined arm beats both single arms | Tested once, 2026, 32 rats: the combined arm did not beat either alone |
| BPC-157 rebuilds tendon | ANIMAL | Rat tendons treated with it failing at the same load as controls | Tested; treated tendons failed at higher loads; never tested in a person |
| ARA-290 regrows nerve fibres | HUMAN | A randomised trial where nerve fibre area does not rise over placebo | Tested; rose 697 µm² over placebo at 4 mg, p=0.012, in sarcoidosis |
| ARA-290 relieves nerve pain from a squeezed nerve root | — | Any randomised trial in that population | Never run. This claim is untested, not supported |
| Any peptide here changes a human disc | — | An imaging trial with a placebo arm | Never run in any species |
| Repeated steroid injections are consequence-free | HUMAN | A matched cohort showing no rise in fracture risk with injection count | Tested; each injection multiplied fracture risk by 1.21 |
| Sleep matters to how a disc feels | HUMAN | A crossover trial where cutting sleep does not change pain thresholds | Tested; 39 volunteers; cutting sleep by 40% raised pain sensitivity, with no change in inflammatory blood markers |

[[embed:source:s15]]

One row deserves adding, because it is the only human evidence that a degenerated disc responds to anything regenerative at all. Pooled across trials of stem cell injection into painful degenerated discs, pain and disability scores improved — small studies, early, and the only positive human regeneration signal that exists for this tissue.

[[embed:source:s6]]

The three rows with no tier are the honest edge of this subject. They are not weak evidence. They are absence of evidence, and they sit in a table rather than in the headline because eleven of the fourteen rows above them have real numbers.

[[embed:herniated-disc]]

## Fifteen people who ran a combination, counted

**Fifteen first-person accounts on X, all self-reported, none verified, none from any trial. Ten of them ran two or more compounds together for a spine problem, and five ran BPC-157 on its own. One further account reports harm from the pair at a different site.**

**Of the ten who stacked, seven reported it helped, two reported partial benefit, and one reported none.**

Three weeks on the pair after an L4-L5 herniation, back on a basketball court against two months last time:

[[embed:source:s22]]

A 2017 L4/L5/S1 herniation with a degeneration diagnosis, and this person says he was pain-free within a month on the pair:

[[embed:source:s23]]

ARA-290 plus BPC-157 plus TB-500 for one month after spine surgery, with the sciatica reported 95% gone:

[[embed:source:s24]]

Lower spine degeneration, barely able to stand upright, and this person reports being pain-free on the pair and still dosing:

[[embed:source:s25]]

Retatrutide alongside a BPC-157/TB-500 blend, low back reported much improved — the only account here combining a weight-loss drug with the peptides:

[[embed:source:s27]]

Three compounds at once for severe back pain, reported cleared in three to four weeks:

[[embed:source:s28]]

Severe leg pain, reported 75% better the same evening and gone by day three:

[[embed:source:s30]]

**Partial — 2 of 10.** One month of the pair for lifelong back pain: recovery between flares got faster, and the pain is still there.

[[embed:source:s26]]

Six weeks of the pair for a dried-out lowest disc: biceps and shoulder pain gone, the disc itself only partly better and still needing physiotherapy.

[[embed:source:s29]]

**No benefit — 1 of 10.** One person ran the pair alongside a second stack for joint damage and called the whole thing a waste of money.

[[embed:source:s31]]

**Of the five who ran a single compound, one reported it helped, three reported nothing, and one reported that one compound did nothing for him while a different one worked.**

L5/S1 herniation, BPC-157 alone and deliberately unpaired, 90% pain reduction in two weeks:

[[embed:source:s33]]

The same compound healing a wrist and doing nothing for the same person's disc:

[[embed:source:s34]]

A week of it to avoid neck surgery; the surgery happened anyway:

[[embed:source:s35]]

Oral capsules taken instead of injections, and no help for a back:

[[embed:source:s37]]

One compound nothing for a back injury, the other clearing it in five days — which is the closest thing in this entire set to a within-person comparison, and it points at the two compounds not being interchangeable:

[[embed:source:s36]]

**Harm — 1 report.** Two months of the pair for knees brought slight improvement in the joints, along with badly disrupted sleep and lowered heart-rate variability. Both the sleep and the heart-rate variability went back to normal after stopping.

[[embed:source:s32]]

**What fifteen accounts settle, and what they cannot.** They cannot compare the stack against a single compound, even though the numbers above look like they do. The stacked group reported a better outcome rate than the single-compound group — 7 of 10 against 1 of 5 — and that difference is worthless as evidence. People who buy three vials have spent more, expect more, and are more likely to post a result. People who describe a null outcome tend to be answering somebody else's thread rather than writing their own. And every single one of these people is running against a background rate where two thirds of herniations resolve regardless.

What the accounts do settle is narrower and still worth having. The reported experience is not uniformly positive: four of fifteen describe no benefit for a spine, and one describes a genuine harm. Timelines that people report cluster at two to six weeks, which is faster than any animal tendon study would predict and is exactly the window in which spontaneous shrinking also happens. Nobody in this set reported a serious adverse event.

## Two registry entries that would move a row each, and a third that is only a template

Two entries on ClinicalTrials.gov are marked recruiting and would each convert one row of the tables above from mechanism into measurement. Neither of them is a disc. A third entry is listed below because it circulates as though it were a trial, and it is not one.

| Registry ID | What it tests | Size | Primary endpoint | Reports |
|---|---|---|---|---|
| NCT07035093 | Retatrutide in people with obesity or overweight and chronic low back pain, phase 3, Eli Lilly | 586 | Pain intensity and body weight change, to 72 weeks | Estimated September 2027 |
| NCT07437547 | BPC-157 for acute hamstring strain, phase 2, Hudson Biotech | 120 | Days to unrestricted sport, and MRI injury volume at day 14 under blinded central review | Estimated February 2027 |
| NCT07487363 | Not a trial. A record that declares itself a fictional example, written in the style of a TB-500 study of cardiovascular markers in stable arterial disease, phase 1/2, Hudson Biotech | 80, stated inside the example | Treatment-emergent adverse events at 12 weeks, stated inside the example | Nothing will ever report |

Read the third row against its own record before counting it. The public summary of NCT07487363 opens: "This fictional study is an example of a ClinicalTrials.gov-style record." Its dose field says the levels "are not provided in this public example." It is a demonstration template, and any page citing it as proof that TB-500 is being tested in people is citing a placeholder. Its sponsor, Hudson Biotech, filed eight entries of that shape between 2 and 15 February 2026, one of which is the BPC-157 hamstring entry in the row above it.

[[embed:source:s18]]

[[embed:source:s19]]

[[embed:source:s20]]

The BPC-157 hamstring trial is the one worth watching, because MRI injury volume under blinded review is the first objective tissue measurement of this compound in a person. If it comes back flat, the entire rat literature stops transferring. If it comes back positive, the disc question becomes worth running rather than worth arguing about.

## What holds always, what holds never, and what depends on something

**Foundational — true with everything else stripped away.** The disc has almost no blood supply and rebuilds slowly. Immune cells and new blood vessels are what remove a herniated fragment. Load, weight, sitting time, smoking and blood sugar act on the breakdown speed. Movement acts on the rebuild speed. BPC-157 and TB-500 are proposed to act on the rebuild speed by improving blood vessel growth and connective tissue repair. ARA-290 acts on nerve fibres, not on the disc.

**Always true.** Two out of three herniations shrink without treatment, so any uncontrolled personal result is uninterpretable. Every steroid injection adds fracture risk in proportion to the count. Any claim about a peptide in a human disc rests on zero measurements in any species.

**Never true.** No compound named on this page is an approved medicine for a disc anywhere in the world. No published experiment has found a bonus from combining BPC-157 with TB-500 — the one experiment that tested it found none. No trial has combined a peptide with exercise, with weight loss, or with an anti-inflammatory.

**Conditional, with the dependency named.** Walking lowers recurrence risk by 28% — in adults who have recently recovered from an episode, over six months of a progressive programme with physiotherapist contact, not in someone in acute pain today. Stopping smoking halts further degeneration and partly restores the gel in the soft centre — in rats, over eight weeks, and it does not reverse the structural misalignment. ARA-290 regrows nerve fibres — in 64 people with sarcoidosis, at 4 mg a day for 28 days, measured in the cornea. BPC-157 strengthens a healing tendon — in rats, injected into the belly, at 10 µg/kg/day, measured at four weeks. TB-500 improves tendon architecture and load to failure — in rats, at 60 µg/kg/day, on the same schedule. Weight loss reduces back pain — against minimal care, and not against exercise.

Red-flag symptoms are the exception to everything above and are not a matter of weighing evidence: loss of bladder or bowel control, numbness across the area that would contact a saddle, or weakness that is getting worse are emergencies and need a hospital the same day. Nothing on this page is a dose, a schedule or a recommendation to take anything, and every compound named is unapproved for disc disease. TB-500 and BPC-157 are both banned in tested sport at all times.

